Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial

Sep 5

Written By Yiran Gan

Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial | Nature Medicine

Article • Open access • Published: 20 June 2024

Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial

Authors: Pepijn Eijsvogel, Pinaki Misra, Luis Concha-Marambio, Justin D. Boyd, Shuang Ding, Lauren Fedor, Yueh-Ting Hsieh, Yu Shuang Sun, Madeline M. Vroom, Carly M. Farris, Yihua Ma, Marieke L. de Kam, Igor Radanovic, Maurits F. J. M. Vissers, Dario Mirski, Ghazal Shareghi, Mohammad Shahnawaz, Wolfgang Singer, Philip Kremer, Geert Jan Groeneveld, Hui Jing Yu & Jean-Cosme Dodart

Source Information

Journal: Nature Medicine volume 30, pages 2631–2640 (2024)

Original Article Link: https://www.nature.com/articles/s41591-024-03101-8

Actions: Cite this article | Save article

Assessing Neurodegenerative Diseases: High-Sensitivity Technologies That Assay Pathological Biomarkers in Blood